- Home
- JHS vs MIST Comparison
JHS vs MIST Comparison
Compare JHS & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JHS | MIST |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.9M | 146.9M |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | JHS | MIST |
|---|---|---|
| Price | $10.89 | $1.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 9.8K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,915.14 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.74 | $1.00 |
| 52 Week High | $12.09 | $3.06 |
Technical Indicators
Market Signals| Indicator | JHS | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 43.94 | 47.88 |
| Support Level | $10.84 | $1.01 |
| Resistance Level | $11.03 | $1.42 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 23.53 | 49.62 |
Price Performance
Historical ComparisonAbout JHS John Hancock Income Securities Trust
John Hancock Income Securities Trust is a United States-based closed-end diversified management investment company. Its main objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.